Pharmaceuticals

A new biotech emerges with massive funding and a next-gen 'shuttle' to deliver safer, more effective Alzheimer's therapies directly to the brain.

Positive early trial data for ZP9830 shows promise for a new class of targeted autoimmune therapies, marking a strategic pivot for Zealand Pharma.

Amid market volatility, the S&P 500 firm reinforces its financial strength with a massive share repurchase program and its 34th year of dividend growth.

As Jazz Pharmaceuticals preps for key investor talks, all eyes are on its blockbuster pipeline, revenue growth, and strategy to fend off competition.

Facing massive revenue declines and a shrinking coach network due to GLP-1 drugs, Medifast bets its future on a risky pivot from weight loss to metabolic health.

Cindy Eckert's TIME100 nod follows a major FDA win for her libido drug, Addyi, but spotlights a decade-long battle over efficacy, safety, and equality.

Genmab posts record 2025 revenue, driven by cancer drug sales and a major acquisition, setting an ambitious, investment-heavy course for 2026.

Primex Inc. hires a life sciences expert to drive its OneVue Sense solution deeper into the critical and highly regulated healthcare and biopharma markets.

ETST announces a major restructuring with executive pay cuts and portfolio changes, projecting $1.4M in savings and positioning for institutional investment.

Sanofi promotes Dupixent growth driver Manuela Buxo to lead its crucial Specialty Care unit, ensuring continuity as competition and a new AI focus intensify.

Accord Healthcare's launch of generic lenalidomide signals a new era of affordability for a key cancer drug, intensifying competition and lowering costs.

A partnership between NSA Labs and Proscia is slashing study times for brain research, showing how digital platforms are key to finding new therapies faster.

A major patent deal shields Esperion's flagship drugs from generics, securing future revenue but delaying cheaper options for millions of patients.

A new oral drug from Nimbus Therapeutics uses AI-driven precision to fight inflammation and repair tissue, offering new hope for millions with IBD.

Cyrano Therapeutics' CYR-064 shows promise in a Phase 2 study, potentially becoming the first approved drug for persistent post-viral smell loss.

With demand for freeze-drying surging, OFD adds project management veteran Danielle Grosso to its expanding leadership team to scale operations.

An independent board again backs the safety of BriaCell's metastatic breast cancer therapy in a pivotal Phase 3 trial, boosting hope for a new treatment.

With a bolstered balance sheet and a sharpened focus, Palatin Technologies is advancing two novel obesity drugs into clinical trials for rare genetic disorders.

Landmark study in JAMA Neurology shows BRIUMVI offers near-zero relapse rates and stable disability, reshaping long-term multiple sclerosis treatment.

NRx Pharmaceuticals gets a green light from the FDA to seek broader approval for its ketamine drug, NRX-100, using a novel real-world evidence approach.